The US regulator has cleared Eohilia (formerly TAK-721), an oral suspension formulation of the well-established steroid drug budesonide, for people 11 years and older with EoE after turning down ...

The Annals of Pharmacotherapy. 2009;43(3):519-527.

Meanwhile, in July the FDA missed its review deadline for Takeda's Eohilia (budesonide oral suspension) treatment for the inflammatory disease eosinophilic oesophagitis, while the EMA extended the ...